海外の治験の状況「%E8%84%B3%E5%8D%92%E4%B8%AD」での検索結果
55件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- An Efficacy and Safety Trial of MK-8931 in Mild to Moderate AD (EPOCH)
- mild to moderate Alzheimer's Disease MedDRA version: 15.0 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Australia, Austria, Belgium, Brazil, Canada, Czech Republic, Denmark, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Portugal, Spain, Turkey, United Kingdom, United States
- 2012-10-02
Authorised
- To evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s Disease (AD)
- Alzheimer's disease MedDRA version: 19.1 Level: LLT Classification code 10001896 Term: Alzheimer's disease System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
- Argentina, Austria, Belgium, Canada, Chile, China, Finland, France, Germany, Hong Kong, Iceland, Israel, Italy, Japan, Korea, Republic of, Mexico, Netherlands, Portugal, Singapore, South Africa, Spain, Taiwan, United Kingdom, United States
- 2017-03-31
Authorised
- Study of oral PHA-848125AC in patients with malignant thymoma previously treated with multiple lines of chemotherapy
- Recurrent or metastatic, unresectable B3 thymoma or thymic carcinoma previously treated with multiple lines of chemotherapy;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy, United States
- 2013-02-27
Authorised
- This is a study to help understand how Baricitinib compares to placebo (a tablet that does not contain any active medicine) in patients with moderate to severe atopic dermatitis, also named atopic eczema
- Atopic Dermatitis MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Czech Republic, Denmark, France, Germany, India, Italy, Japan, Mexico, Russian Federation, Taiwan
- 2017-08-29
Authorised
- This is a study to help understand how Baricitinib compares to placebo (a tablet that does not contain any active medicine) in patients with moderate to severe atopic dermatitis, also named atopic eczema
- Atopic Dermatitis MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Czech Republic, Denmark, France, Germany, India, Italy, Japan, Mexico, Russian Federation, Taiwan
- 2017-09-04
Authorised
- Efficacy, Safety, and Pharmacokinetic Profile of ANB020 in Adults with Moderate to Severe Atopic Dermatitis
- Moderate-to-Severe Atopic Dermatitis MedDRA version: 20.0 Level: PT Classification code 10012438 Term: Dermatitis atopic System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Canada, Czech Republic, Germany, Poland, United Kingdom, United States
- 2018-06-20
Authorised
- Efficacy, Safety, and Pharmacokinetic Profile of ANB020 in Adults with Moderate to Severe Atopic Dermatitis
- Moderate-to-Severe Atopic Dermatitis MedDRA version: 20.0 Level: PT Classification code 10012438 Term: Dermatitis atopic System Organ Class: 10040785 - Skin and subcutaneous tissue disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Canada, Czech Republic, Germany, Poland, United Kingdom, United States
- 2018-05-23
Authorised
- A study to assess the safety and efficacy of ZPL389 doses in subjects with moderate to severe atopic dermatitis
- Moderate to severe atopic dermatitis MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Canada, Finland, Germany, Iceland, Japan, Netherlands, Poland, United Kingdom, United States
- 2018-05-16
Authorised
- A study to assess the safety and efficacy of ZPL389 doses in subjects with moderate to severe atopic dermatitis
- Moderate to severe atopic dermatitis MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Canada, Finland, Germany, Iceland, Japan, Netherlands, Poland, United Kingdom, United States
- 2018-04-12
Authorised
- A study to assess the safety and efficacy of ZPL389 doses in subjects with moderate to severe atopic dermatitis
- Moderate to severe atopic dermatitis MedDRA version: 20.0 Level: LLT Classification code 10003639 Term: Atopic dermatitis System Organ Class: 100000004858 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Canada, Finland, Germany, Iceland, Japan, Netherlands, Poland, United Kingdom, United States
- 2018-03-05